Landsittel Michael 4

What Happened

• Michael Landsittel, a director of Damora Therapeutics, was granted a derivative award on March 23, 2026: an option covering 37,313 shares of common stock with an acquisition price reported as $0.00. This filing reports a grant (award) rather than an open‑market purchase or sale, so no cash changed hands at grant.

Key Details

• Transaction date: 2026-03-23; Form 4 filed: 2026-03-25 (appears timely).
• Transaction type/code: A (Award/Grant of derivative).
• Shares/units involved: option to acquire 37,313 shares; reported exercise/acquisition price $0.00 in the filing.
• Vesting: option vests in equal monthly installments through March 23, 2029, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No immediate exercise/sale: this is a grant of an option (not an exercised or sold position) and does not indicate an immediate cashless exercise or disposition.

Context

• As an option grant to a director, this is typically a retention/incentive award tied to future service and vesting, not a present purchase or sale signal. Retail investors should view it as management compensation rather than an immediate endorsement via purchase.